Role of Antibody-Drug Conjugates in Multiple Myeloma

In this episode, experts discuss the reemergence of the antibody-drug conjugate belantamab and how it fits into a treatment landscape now dominated by bispecific antibodies and cellular therapies. Panelists explain that belantamab may offer an important option for patients who lack equitable access to bispecific T-cell engagers or CAR T therapy, especially in community settings more familiar with antibody drug conjugates. They note ongoing questions about sequencing, emphasizing that diminished responses seen when CAR T follows prior BCMA bispecific exposure have not yet been observed with belantamab. Experts highlight belantamab’s potential as an off-the-shelf therapy that can serve as a bridge for patients unable to reach specialized centers. They also reference data from the DREAMM-7 study showing progression-free survival approaching 30 months, positioning belantamab as a meaningful alternative for certain patients.